---
schema_version: "secwatch.filing_event.v1"
accession: "0001628908-23-000119"
form_type: "8-K"
ticker: "EVH"
cik: "0001628908"
company_name: "Evolent Health, Inc."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T13:47:04.398697+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Evolent Q2 revenue up 47% to $469M, raises 2023 Adj. EBITDA guidance; redeems $24.3M convertible notes

## Summary
- Revenue $469.1M (+46.6% YoY); net loss $41.4M; adjusted EBITDA $47.4M (10.1% margin).
- Total Lives on Platform 78.6M (from 19.4M); average unique members 41.8M (from 16.3M).
- Signed 2 new operating partners (Molina Florida, regional non-profit) and 2 expansions; YTD 6 deals vs target 6-8.
- CEO raises 2023 Adj. EBITDA guidance; reaffirms $300M run-rate target exiting 2024.
- Redeeming $24.3M of 3.50% convertible notes due 2024 on Oct 13 for cash (100% principal + interest).

## SEC filing metadata
- accession: 0001628908-23-000119
- form_type: 8-K
- ticker: EVH
- cik: 0001628908
- company_name: Evolent Health, Inc.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628908/000162890823000119/0001628908-23-000119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628908/000162890823000119/evh-20230802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628908-23-000119
- JSON: https://secwatch.observer/filing/0001628908-23-000119.json
- Plain text: https://secwatch.observer/filing/0001628908-23-000119.txt

## Key facts
- Earnings Releases
  Evolent Health, Inc. reported the quarter ended June 30, 2023 results: revenue $469.1 million, net income Net loss attributable to common shareholders of Evolent Health, Inc. of $41.4 million. Guidance raised.
  - Period: the quarter ended June 30, 2023
  - Revenue: $469.1 million
  - Net income: Net loss attributable to common shareholders of Evolent Health, Inc. of $41.4 million
  - Guidance: raised
  - Result: reported results
  source text: simpler and more affordable, today announced financial results for the quarter ended June 30, 2023. Highlights from the second quarter 2023 announcement include: • Revenue of $469.1 million, an increase of $149.2 million, or 46.6%, from the three months ended June 30, 2022. • Net loss attributable to common shareholders of Evolent Health, Inc. of $41.4 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628908/000162890823000119/0001628908-23-000119-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.